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PR1 is also processed and presented by NE, which may result in 
enhanced immunogenicity of the peptide conapared to peptides 
derived from a single protein. Redundancy of proteins may also 
lessen the impact of tumor loss variants after PRl-based 
immunotherapy. 
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TREATMENT OF DONORS WITH INTERLEUKIN-18 REDUCES ACUTE 
GRAFT-VERSUS-HOST DISEASE VIA STAT6 AND PRESERVES CD8 ÷ 
MEDIATED GRAFT-VERSUS-LEUKEMIA EFFECTS 
Reddy, p.t; Teshima, T.I; IJildebrandt, G J; ~(illiams, D.I; Liu, C?; 
Cooke, IvY; FeJv'ara, J.LJ 1. lnte~'nal Medicine, UMve1"sity of k/Iichi- 
gan Medical CeT~ter, Am7 A't'bor, MI; 2. Unive't'sity of Flo~'ida, 
GaineswTle, FL. 
haterleukin 18 modulates both Thl/Th2 responses and stimulates 
hcmatopoietic growth factor secretion. VVe investigated the effect of 
pretreating bone marrow transplant (BMT) donors with IL- 18 on the 
severity of acute GVHD using a well-characterized irradiated experi- 
mental BMT model (BALB/c(H-2d-~ B6 (H-2u). Pretreatment of 
allogeneic BMT donors with IL-18 (lpg/day of rmIL-18 for 10 days, 
day 11 to -1) significantly improved survival, and caused significant 
reduction in serum levels of TNF-c~(212 +18pgJml vs 524 +69pg/ml, 
P<0.05)and LPS (5.3 --1.1U/ml vs 12.4 _+l.3U/ml, P<0.05) and 
GVHD related intestinal histopathology (P<0.05). All surviving mice 
showed complete donor engTafunent, hus ruling out graft rejection 
and mixed chimerism as causes for decreased GVHD. IL-18 pretreat 
naent was also associated with reduced IFN- 7 (1987 -+387pg/ml vs 
4686 _+964p~ml, P<0.03) and greater IL-4 secretion (54.8 _+9.3pgkni 
vs 14.5 _+3.4pg/ml, P<0.04) by donor T cells after BMT. Surprisingly, 
when IFN-ydeficient 1nice were pretrcated with rmIL-18 and used as 
donors acute GVIID mortality was reduced thus ruling out the role 
of donor IFN-Tin this effect. Acute GVHD mortality was also 
reduced when IL-18 was administered to donors deficient in STAT4. 
Treannent of STAT6 deficient donors with IL-18 did not alter IFN- 
7 secretion (14.3 _+2.I ng/ml vs 10.2 _+3.8ng/mI, P=NS) or enhance 
IL-4 production. Furthermore pretreatment of STAT6-/ donors 
with IL-18 did not reduce acute GVHD mortality thus confirming 
the role of STAT6 signaling in IL-18's protective ffect. "eVe next 
investigated whether IL-18 can maintain a graft-versus-leukemia 
(GVL) effect using the same model and by injecting recipients with 
host-type (H-2 b) EL-4 MHC II-/-lymphoma cells at the time of 
BMT. IL-18 txeamlent did not alter donor CD8 + cytotoxic T lym 
phocyte (CTL) activity" and preserved graft versus leukemia (GVL) 
effects after allogeneic BMT (70% v I0%, P < 0.01). Our results 
demonstrate hat pretreatment of donors with IL-18 preserves the 
CD8 + mediated GVL effects but reduces acute GVHD in a donor 
derived IFN 3*independent but in a STAT6 dependent mechanism. 
94 
TACROLIMUS (FK-506) AND MYCOPHENOLATE MOFETIL (MMF) 
GVHD PROPHYLAXIS IN ALLOGENEIC SCT (ALLOSCT) RECIPIENTS: 
ALTERED MMF PHARMACOKINETICS (PK) ASSOCIATED WITH AGVHD 
BessT~es~:JTy, 0.; Ostmkwo, I.; Ha~v'ison, L.; Wolownik, K.; Wischhove'/', C.; 
Gatvin, ft.; Geo*ge, D.; Del Tovo, G.; Bradley, M.; Cairo, M.& CblTd'J'en's 
Hospital of New YoJ'k PT"esbyteHan, Columbia University, New York, NI( 
FK-506/NLMF is an effective salvage therapy for steroid-refrac- 
tory chronic (C) GVHD (Mookerjee t al, BMT 1999; 24:517-20) 
and has been used for prophylaxis of acute (A) and C GVHD fol 
lowing nonmyeloablative conditioning in adults (Rini BI et al, 
JCO 2002; 20:2017-203. We investigated safety and efficacy of 
FK-506/MMF regimen for GVHD prophylaxis to spare th use of 
methotrexate (MTX) and steroids in 29 pts (mean age 8.5 [range 
0.5-22 years]; 21 M, 8 F) undergoing 32 AlloSCT for hematologic 
malignancies (n=20), non-malignant disorders (n=7), and neurob- 
lastoma (n=2). GVHD prophylaxis included FK-506 0.03 
mg/kg/day continuous 1V on Day -1 or 1st day of conditioning 
plus MMF 15 mg/kg/dose PO/IV BID starting Day +1. Doses of 
FK-506 and MMF were adjusted to maintain concentrations with- 
in reference ranges of 5-20 ng/mL for FK-506 and 1-3.5 mcg/mL 
for mycophenoleic a id (MPA). HLA typing was serologic for A 
and B and high resolution DRB1. Stem cell sources were 6/6 
UCB (n=43, 5/6 UCB class I mismatch (n=4), 4/6 UCB (mismatch: 
class I [n=8], class II [n-l], double class I/II [n=3]), 6/6 related (R) 
BM (n=3), 6/6 RPBSCT (n=8), 5/6 RPBSCT class I mismatch 
(n=l). kanong 28 evaluable pts, mean days to ANC _>500/ram 3 x 2 
days was 14 (11-17) and 27 (8-70) following related RPBSCT/BM 
and UCB, respectively. Fifteen pts (53.6%) developed ->grade II
AGVHD: 7 RBM/PBSC and 8 UCB. The incidence of grade 
III/IV AGVHD was 32% (5 RBM/PBSC and 4 UCB) and 6% for 
CGVHD (n=2). FK-506/MMF was well tolerated, with 2 episodes 
of grade I I I - IV neurotoxicity (disorientation and leukoen- 
cephalopathy). M PA trough concentrations were monitored in the 
second half of the study (n=123. Eight pts developed AGVHD and 
7 bad MPA below target range (<1 mcg/ml) at GVHD onset. 
MMF doses >900 mg/m 2 IV/PO q6h (4 times standard ose) were 
required to achieve target MPA trough concentrations in the early 
AlloSCT period (< Day +30). Five of 12 pts monitored achieved 
target MPA levels before Day +30 and the incidence of >Grade III 
AGVHD was 20%. The estimated 1-year OS is 52.1%. These 
results uggest that FK506/MMF is a safe and effective MTX and 
steroid sparing GVHD prophylaxis regimen following R and 
UCB AlloSCT. Further pharmacokinetic and pharmacodynamic 
studies are ongoing in AlloSCT recipients to define the optimal 
dosing regimen of A~V[F. 
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CD83 ANTIGEN: A POTENTIAL NEW TARGET FOR GRAFT VERSUS 
HOST DISEASE PREVENTION 
Ml~7~steT; D.J.; Kato, J¥l.; 3/lacDo~ald, K.P., Rice, A.M.; Hart, D.N. 
Cance'r ]3iotheT~ap~, Mater Medical Researeh Institztte, Soath BvisbaTze, 
QLD, Aust1"alia. 
Novel strategies are required to overcome the limitations imposed 
on hematopoietic stem cell transplantation by graft versus host dis- 
ease (GVHD). Cm'rent GVHD therapies focus on elimination or 
attenuation f the effcctor T cell. There is emerging evidence in the 
literature to suggest a primary role for dendritic ells (DC) in the 
initiation of GVHD. CD83 is a marker of DC differentiation/activa- 
tion. Polyclonal anti-CD83 antibody (RA83) inhibits the T lympho- 
cyte proliferative response in the mkxed leukocyte reaction (MLR) 
stinmlated by allogeneic monocyte derived DC (MoDC). We inves- 
tigated the mechanism of tltis RA83 mediated immunosuppression 
and found that it was not due to functional blockade of CD83. It 
required the presence of NK-cclls, Fab fragments of RA83 did not 
inhibit the MLR, and treatment with an Fc7 receptor III (CD16) 
blocldng monoclonaI antibody (3G8) prevented the blockade, indi- 
cating that it was due to antibody dependent cellular cytotoxicity 
(ADCC) of CD83 + cells. In additional experiments we showed that 
activated NiL<ells lyse 5/~Cr labelled CD83 + MoDC in the presence 
of RA83, but not in the presence of non-immune polyclonal anti- 
body. hnmamre CD83 MoDC were not lysed in the presence of 
RA83. However, lysis of MoDC did not account for all the effect 
because stimulation with allogeneic MoDC fixed with paraformalde- 
hyde also exhibited inhibition of T lymphocyte proliferation i  the 
presence of RA83. This implied that CD83 + targets of ADCC must 
exist or arise in the responder cell preparation. YVe then established 
that activated blasting T<ells (CD25 +, Ki67 +) stimulated by allo- 
geneic MoDe also express CD83 and that they become targets of 
NK-cell mediated ADCC. Thus, CD83 is expressed by both stimu- 
lator and responder cells in the MLR. Simultaneous targeting of 
both activated cell populations by a single reagent such as anti- 
CD83 may be a potent means of achieving therapeutic imnmnosup- 
pression for allogeneic hematopoietic stem cell transplantation. 
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IMPROVED OUTCOME IN ACUTE LETHAL MURINE GRAFT VERSUS 
HOST DISEASE (GVHD) FOLLOWING ADMINISTRATION OF THE PRO- 
TEASOME INHIBITOR PS-341 
Webziak, L.AJ; &m, K.2; Sayevs, T.J.2; Mzlrpby, I4~J. l I. Microbiolo- 
gy, University of Nevada, Rent, Rent, NV; 2. SAIC-t;rederick, Freder- 
ick, 3lID. 
Proteasome inhibitors have recently shown much promise by 
selectively acting on various neoplastic ells, particularly" myelo- 
mas. We have recently found that the use of proteasome inhibi- 
tion with PS-34I sensitizes neoplastic ells to TRAIL mediated 
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ldlling and can be used to purge leukemic cells fi'om hematopoiet- 
ic stenr cell (HSC) products in an experimental nmrine transplan 
ration model. We now wish to extend our studies to examine the 
use of PS-341 administration post-HSC transplant. We hypothe- 
sized that PS-341 would reduce GVHD associated mortality by 
preventing degradation of IkB leading to decreased NF-kB DNA 
binding activity and NF-kB dependent cytokinc production. V~Ze 
tested tire efficacy of PS-341 administration i a full MHC mis- 
matched routine model of acute lethal GVHD. C57BL/6 bone 
marrow and splenocytes were transplanted into lethally irradiated 
BALB/c hosts. PS-341 (lmg/kg) was administered on the day of 
transplant and also at later time points in some groups. Under 
experimental conditions where animals that receive vehicle con- 
trol succumb to acute GVHD within 12 days of transplant, mice 
that received PS-34l on the day of transplant are protected from 
lethal disease (log rank test p< 0.0001). However, administration 
of PS-341 dur ing the first week post - t ransplant  resulted in 
markedly accelerated mortality due to GVHD.  These studies 
demonstrate that the proteasome inhibitor PS-341 can be given 
concurrent with allogeneic HSC transplantation and can reduce 
early lethal acute GVHD although timing of the administration is 
critical. 
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TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA (CML) RELAPS- 
ING AFTER MYELOABLATIVE STEM CELL TRANSPLANTATION WITH 
STI-571 (IMATINIB MESYLATE) WITH OR WITHOUT DONOR LYM- 
PHOCYTE INFUSION (DLI) 
Barrett, ~.A.; Battiz~ala, M.; Solm~lom S.; Cbilds, R.; Hem'el, ~ ;  TVebvleJl, 
L.; Kztrlamtet; R. Stezzt Cell AllogeJzeic Tl:allspla~itatioJl Sectio~, Helmztol- 
o W B*'aT~ch, NHLBI, NatiolTal h~stitutes ofHealtb, DHHS, Betbesda, MD. 
CML relapsing after allogencic stem cell transplantation (SCT) can 
be successfully retreated with DLI. However DLI can cause GVHD 
and is less effective for hematological relapse. We therefore used 
STI-571 to treat patients with CML relapsing after SCT following 
myelobalative preparative regimens. Ten patients (9 who had not 
received STI-571 pretransplant) relapsed 4-36 months post trans- 
plant. Five were molecular elapses, five were more advanced ( kary- 
otypic = 1, chronic phase (CP) = 2, blast crisis (BC) =2). STI-571 300- 
600 rag/day was given to all patients who had a minimum of two 
positive RT-PCR assays *2 months apart, or who developed hemato- 
logical relapse. Prior to treatment, immtmosuppression was stopped 
on all patients (n=9) without active GV~tD. STI as a single agent was 
given to 5 molecular eIapses. Two had failed prior DLI. Four 
patients prompdy became PCR negative within 6 weeks. However 
three had a molecular relapse after STI was stopped and are currently 
retreated. STI 571 combined with 1-5 xl07/kg CD3+ DLI was given 
to 5 patients relapsing with more advanced CML. Three (CP or kat T- 
otypic relapse) achieved complete molecular emissions, sustained in 
two. One myeloid BC patient developed extensive chronic GVHD 
after DLI given day 100 to treat persisting molecular disease, STI was 
stopped because of thrombocytopeuia, he progressed with chloromas 
by 5 months post-transplant but has achieved a stable molecular 
remission persisting >6 months after restarting STI 600rag/day. One 
patient relapsing in ALL BC achieved a hematological remission but 
relapsed again 3 months later and died of disease progTession.Thus, 
of I0 STI-txeated patients, 7achieved molecular remission which was 
sustained in 4. These results uggest hat the cytoreductive action of 
STI can synergize with the graft-versus-leukemia effect. However, 
the tendency for further elapse when STI is withdrawn suggests that 
cure of relapsed CML may also require a GVL effect. 
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INFUSION OF HIGH NUMBERS OF G-CSF MOBILIZED BLOOD DEN- 
DRITIC CELLS TYPE 2 (DC-2) IS ASSOCIATED WITH AN INCREASED 
RATE OF CHRONIC GVHD IN ALLOGENEIC PBSC TRANSPLANTATION 
Rm~delli, D2; Avpi~lati, M. 7, CtJi'J'zcmbolo, G.1; UvbiHi, B.~; BoJ~tzi, 
F J; Sm~zaJzi, M.t; Falcimzi, S.I; BmzdiJzi, G.~; Baccava~i, M. s 1. U~zi- 
ve'~'sit~ ofllli~zois at Chicago, Ste~zz Cell T~'mzspla~t P~'og~w~n, Cb#ago, 
IL; 2. U~zivers#y of Bohwza, Bolog~za, Italy. 
It was previously shown that dendritic cells type-2 (DC-2) are 
significantly increased in G-CSF-mobil ized leukapheresis prod- 
ucts as compared to unstimulated bone marrow. In this study, we 
analysed whether the numbers of DC-1 and DC-2, as well as of 
other cell components in the graft, was associated with acute 
and/or chronic GVI ID in 31 adult patients (11 MM, 7 CML CP, 
6 AML, 5 NHL,  and 2 MDS) receiving an allogeneic PBSC trans- 
plant from HLA-lnatched siblings. Average cell doses (xl06/kg) in 
the grafts were the following: 283_+137 CD3+ T ceils, 160_+88 
CD4+ T lymphocytes, 116_+55 CDS+ T lymphocytes, 64_+39 
CD19+ B lymphocytes, 51_+29 CD56+ NK cells, 253_+103 CD14+ 
monocytes, 6.6+4.1 CD34+ cells, 2.1_+0.9 HLA-DR+lin-CD i I c+ 
DC-1 and 2.9_+1.3 HLA-DR+lin-CD123+ DC-2. Median follow 
up was 255 days (range: 50-685). Patients were initially divided in 
three groups according to whether they had shown no signs of 
acute GVHD (grade 0, n=10), acute GVHD grade I (n=12), or 
grade II - IV (n=9). Median numbers of CD34+ cells, lymphocyte 
subsets, and DC-1 and DC-2 received by patients in these three 
groups did not differ significantly. Of 21 patients with adequate 
follow up (median 485 days, range: 131-695) 12 developed chronic 
GVHD (10 extensive, 2 limited). Analysis of cell components of 
the grafts demonstrated that patients developing chronic GVHD 
had received a signifcantly higher dose of DC-2 than patients 
without chronic GVHD (3.3+_1.5 vs 2.2_+0.9, p=0.05), while the 
dose of DC-1 (p=0.7), monocytes (p-0.28), T lymphocytes 
(p=0.643), B lymphocytes (p=0.939), NK  cells (p=0.487) and 
CD34+ cells (p=0.757) was not different. Also, chronic GVHD did 
not correlate with recipient or donor age or gender, interval 
between diagnosis and transplant, presence of ATG or TBI in the 
conditioning regimen, or type of GVHD prophylaxis. Our results 
suggest hat the presence of large DC-2 numbers in the graft may 
be associated with a higher risk of chronic GVHD after allogeneic 
PBSC transplantation. These data might prompt further studies 
addressing whether depletion of graft DC-2 might be beneficial in 
this setting. 
99 
SOLID TUMOR VACCINES ELICIT DISTINCT IMMUNE RESPONSES 
FROM HOST VERSUS DONOR T CELLS IN MIXED CHIMERAS CREATED 
BY NON-MYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTA- 
TION (NST) 
Dzll:atcovic, NJ; Slmzsk~ , ,7.E.e; Pmdoll, I).MS; Fucbs, E.J.1; Lt~zMk, 
LJ 1. The Sidemen, Ki71zTnel Cmz~p~'ehe~zsive Cm~ceT- Cez~te1" at ffohlzs Hop- 
kiJzs, Balti71zore, AJD; 2. Dept. of bz~'mztz~ology, UJziv. of Colo~wdo 
Health &'ieJzces CeJ~te~5 DeTzve~, CO. 
A growing body of evidence suggests that functional unrespon- 
siveness of the immune system to growing solid tumors may be 
due to tolerance in minor-specific CD4 + T cells, whereas tumor 
specific CD8 + T cells exist in a state of partial activation with lim- 
ited effector function. We therefore hypothesized that an allo- 
geneie graft-versus host reaction may provide a helper effect that 
augments the anti-tumor immune response of host CD8 + T cells 
in mixed henaatopoietic chimeras. To test this hypothesis, we ana- 
lyzed host versus donor T cell responses to AH1, an H-2L 'u- 
restricted tumor antigen expressed by CT-26, a colon cancer of 
BALB/c mice. BALB/c mice with pre-established subcutaneous 
tumor underwent NST  from MHC-compatible B10.D2 donors. 
Two weeks later, groups of chimeras received nothing, B10.D2 
splenocytes IV, CT-26 tumor vaccine (irradiated CT-26 cells 
mixed with a GM-CSF secreting bystander cell line), or both. By 
staining with H-2L d tetramers loaded with the AHI 423-431 a.a. 
peptide, AHl-specific CD8 + T ceils were found to comprise 2-3% 
of total spleen CD8 + T cells three weeks after vaccination. In con- 
trast~ AHl-specific T cells could not be detected in the non-trans- 
planted, tumor hearing mice. To flirther characterize AHl-specif 
ic T cells we characterized T cell avidity for antigen, as measured 
, by binding ofAH1 peptide-loaded, L ~ IgG dinnners. AH1 specific 
T cells were easily expanded in vitro using AH-1 peptide pulsed 
irradiated BALB/c splenocytes. After four weeks of stimulation 
the highest percentages of cultures containing AHl-specif ic T 
cells were derived from tumor-bearing chimeras that received 
B10.D2 splenocytes and a CT-26 vaccine. Expanded cultures con- 
tained AH-1 specific CD8 + T cells derived front the host and the 
donor, based on the differential expression of Ly9.1 marker on the 
94 
